End-of-day quote
Taipei Exchange
06:00:00 2024-05-05 pm EDT
|
5-day change
|
1st Jan Change
|
57.1
TWD
|
+7.33%
|
|
+7.74%
|
+46.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
669.2
|
685
|
598.9
|
601.3
|
664.4
|
988.3
|
Enterprise Value (EV)
1 |
450.9
|
454.1
|
390.4
|
404.8
|
409.3
|
722.5
|
P/E ratio
|
40
x
|
37.7
x
|
-38
x
|
77.5
x
|
26.1
x
|
34.7
x
|
Yield
|
2.27%
|
2.4%
|
-
|
1.17%
|
1.74%
|
1.31%
|
Capitalization / Revenue
|
1.75
x
|
1.6
x
|
1.35
x
|
1.16
x
|
1.21
x
|
1.67
x
|
EV / Revenue
|
1.18
x
|
1.06
x
|
0.88
x
|
0.78
x
|
0.75
x
|
1.22
x
|
EV / EBITDA
|
27.4
x
|
28.6
x
|
-23.9
x
|
226
x
|
15.3
x
|
29.1
x
|
EV / FCF
|
46.5
x
|
-91.7
x
|
-1,181
x
|
-20.9
x
|
11.5
x
|
21.9
x
|
FCF Yield
|
2.15%
|
-1.09%
|
-0.08%
|
-4.79%
|
8.69%
|
4.57%
|
Price to Book
|
2.07
x
|
1.99
x
|
1.92
x
|
1.89
x
|
1.91
x
|
2.3
x
|
Nbr of stocks (in thousands)
|
25,405
|
25,405
|
25,405
|
25,405
|
25,405
|
25,405
|
Reference price
2 |
26.34
|
26.96
|
23.57
|
23.67
|
26.15
|
38.90
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/30/22
|
3/30/23
|
3/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
381.7
|
429.4
|
443.1
|
519.5
|
547.8
|
592.5
|
EBITDA
1 |
16.48
|
15.89
|
-16.36
|
1.792
|
26.7
|
24.81
|
EBIT
1 |
11.56
|
11.28
|
-21.58
|
-4.529
|
20.15
|
18.58
|
Operating Margin
|
3.03%
|
2.63%
|
-4.87%
|
-0.87%
|
3.68%
|
3.14%
|
Earnings before Tax (EBT)
1 |
18.09
|
20.89
|
-18.28
|
10.2
|
33.19
|
34.74
|
Net income
1 |
16.88
|
18.3
|
-15.7
|
7.839
|
25.73
|
28.56
|
Net margin
|
4.42%
|
4.26%
|
-3.54%
|
1.51%
|
4.7%
|
4.82%
|
EPS
2 |
0.6586
|
0.7158
|
-0.6204
|
0.3054
|
1.002
|
1.120
|
Free Cash Flow
1 |
9.702
|
-4.949
|
-0.3306
|
-19.39
|
35.56
|
32.99
|
FCF margin
|
2.54%
|
-1.15%
|
-0.07%
|
-3.73%
|
6.49%
|
5.57%
|
FCF Conversion (EBITDA)
|
58.88%
|
-
|
-
|
-
|
133.19%
|
132.99%
|
FCF Conversion (Net income)
|
57.46%
|
-
|
-
|
-
|
138.19%
|
115.5%
|
Dividend per Share
2 |
0.5982
|
0.6484
|
-
|
0.2777
|
0.4558
|
0.5100
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/30/22
|
3/30/23
|
3/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
218
|
231
|
208
|
197
|
255
|
266
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
9.7
|
-4.95
|
-0.33
|
-19.4
|
35.6
|
33
|
ROE (net income / shareholders' equity)
|
5.33%
|
5.53%
|
-4.7%
|
2.54%
|
7.79%
|
7.4%
|
ROA (Net income/ Total Assets)
|
1.85%
|
1.68%
|
-3.17%
|
-0.68%
|
2.86%
|
2.21%
|
Assets
1 |
912.1
|
1,091
|
494.7
|
-1,155
|
899.3
|
1,293
|
Book Value Per Share
2 |
12.70
|
13.60
|
12.30
|
12.60
|
13.70
|
16.90
|
Cash Flow per Share
2 |
2.780
|
1.750
|
2.700
|
3.360
|
2.260
|
5.060
|
Capex
1 |
2.7
|
1.89
|
8.87
|
7.95
|
7.05
|
3.73
|
Capex / Sales
|
0.71%
|
0.44%
|
2%
|
1.53%
|
1.29%
|
0.63%
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/30/22
|
3/30/23
|
3/25/24
|
|
1st Jan change
|
Capi.
|
---|
| +46.79% | 44.87M | | -14.37% | 11.65B | | +70.73% | 3.88B | | -29.39% | 2.33B | | -12.90% | 2.2B | | +37.56% | 1.2B | | -2.40% | 758M | | -15.17% | 529M | | -34.29% | 475M | | +13.72% | 338M |
Bio Diagnostics & Testing
|